Literature DB >> 9827824

Complete-type DiGeorge syndrome treated by bone marrow transplantation.

T Matsumoto1, N Amamoto, T Kondoh, M Nakayama, T Takayanagi, Y Tsuji.   

Abstract

BMT was carried out on a patient with DiGeorge syndrome who suffered recurrent infections after birth. At 13 months of age, 8.0 x 10(8)/kg of bone marrow nuclear cells were infused from an HLA-identical sibling using only anti-thymocyte globulin to prevent rejection. Donor DNA was not detected on microsatellite polymorphism by PCR. At 19 months of age, a second BMT from the same donor was carried out using busulfan and cyclophosphamide as conditioning. DNA examination of bone marrow showed chimerism at day 18 and complete donor origin at day 28. Seven months post-BMT, the numbers of CD3-, CD4- and CD8-positive cells were in the normal range. BMT is thus an effective therapy for DiGeorge syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827824     DOI: 10.1038/sj.bmt.1701475

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly.

Authors:  Ales Janda; Petr Sedlacek; Manfred Hönig; Wilhelm Friedrich; Martin Champagne; Tadashi Matsumoto; Alain Fischer; Benedicte Neven; Audrey Contet; Danielle Bensoussan; Pierre Bordigoni; David Loeb; William Savage; Nada Jabado; Francisco A Bonilla; Mary A Slatter; E Graham Davies; Andrew R Gennery
Journal:  Blood       Date:  2010-06-07       Impact factor: 22.113

2.  Immunologic reconstitution in 22q deletion (DiGeorge) syndrome.

Authors:  Sean A McGhee; Maria Garcia Lloret; E Richard Stiehm
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

3.  Sickle Cell Disease with Cyanotic Congenital Heart Disease: Long-Term Outcomes in 5 Children.

Authors:  Glen J Iannucci; Olufolake A Adisa; Matthew E Oster; Michael McConnell; William T Mahle
Journal:  Tex Heart Inst J       Date:  2016-12-01

4.  Persistent low thymic activity and non-cardiac mortality in children with chromosome 22q11.2 microdeletion and partial DiGeorge syndrome.

Authors:  P Eberle; C Berger; S Junge; S Dougoud; E Valsangiacomo Büchel; M Riegel; A Schinzel; R Seger; T Güngör
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

Review 5.  Esophageal atresia and tracheo-esophageal fistula associated with coarctation of the aorta, CHARGE association, and DiGeorge syndrome: a case report and literature review.

Authors:  Kyeong Deok Lee; Tadaharu Okazaki; Yoshifumi Kato; Geoffrey J Lane; Atsuyuki Yamataka
Journal:  Pediatr Surg Int       Date:  2008-10       Impact factor: 1.827

6.  FISH investigation of 22q11.2 deletion in patients with immunodeficiency and/or cardiac abnormalities.

Authors:  Tahsin Yakut; Sara Sebnem Kilic; Ergun Cil; Esra Yapici; Unal Egeli
Journal:  Pediatr Surg Int       Date:  2006-02-04       Impact factor: 1.827

7.  Post-natal ontogenesis of the T-cell receptor CD4 and CD8 Vbeta repertoire and immune function in children with DiGeorge syndrome.

Authors:  Caterina Cancrini; Maria Luisa Romiti; Andrea Finocchi; Silvia Di Cesare; Patrizia Ciaffi; Claudia Capponi; Savita Pahwa; Paolo Rossi
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.542

Review 8.  The DiGeorge anomaly.

Authors:  R Hong
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 10.817

Review 9.  Molecular Insights Into the Causes of Human Thymic Hypoplasia With Animal Models.

Authors:  Pratibha Bhalla; Christian A Wysocki; Nicolai S C van Oers
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

10.  Placental transfer of maternally-derived IgA precludes the use of guthrie card eluates as a screening tool for primary immunodeficiency diseases.

Authors:  Stephan Borte; Magdalena Janzi; Qiang Pan-Hammarström; Ulrika von Döbeln; Lennart Nordvall; Jacek Winiarski; Anders Fasth; Lennart Hammarström
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.